At the news
? BEARISHIMPACT 6/10 8-K filed May 27, 2026 at 16:15 ET
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy programs, losing options for four new CNS indications. Separately, the company paid $2.3 million to exit its 37,000 sq ft Philadelphia office lease, consistent with its remote-only model. The Gemma termination removes a key pipeline catalyst for a $19M market cap biotech with no approved products.
- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, plus options for four new CNS indications.
- Paid $2.3 million termination fee to exit 37,000 sq ft office lease at 2005 Market Street, Philadelphia.
- Company operates as remote-only with no headquarters; lease was set to expire December 2031.
- Market cap is approximately $19 million with no disclosed revenue from product sales.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access